Arkolith/Insider Trading/INBX/Form 4

Lappe Mark

Chief Executive Officer, DirectorInhibrx Biosciences, Inc. (INBX) · full profile →Form 4 · filed Aug 22, 2024
Net Buying
Open-Market Buys
$518K
Open-Market Sells
$0
Net Open-Market Flow
$518K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 21, 2024Buy(P)13K$12.93$167K55K
Aug 20, 2024Buy(P)27K$12.97$351K42K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002007919-24-000038) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML